Safety and efficacy of first-line chemotherapy in unresected metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 6, Issue 10, 2007, Pages 710-715

  Puthillath, Ajithkumar ^a   Dunn, Kelli Bullard ^a   Rajput, Ashwani ^a   Smith, Judy ^a   Yang, Gary ^a   Wilding, Gregory E ^a   Tan, Wei ^a   Gupta, Bhavna ^a   Fakih, Marwan G ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

5 Fluorouracil; Bowel obstruction; FOLFIRI; FOLFOX; Irinotecan; Leucovorin; Oxaliplatin; Palliative treatment

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; COLON CANCER; COLON OBSTRUCTION; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; RECTUM TUMOR; SYMPTOM; TREATMENT OUTCOME;

EID: 36849074724     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2007.n.040     Document Type: Article

References (19)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56:106-30.
2. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-47.
3. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905-14.
4. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-47.
5. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30.
6. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-37.
7. Fuchs C, Marshall J, Mitchell E, et al. Updated results of BICC-C study comparing first-line irinotecan/fluoropyrimidine combinations ± celecoxib in mCRC: clinical data cut-off September 1, 2006. Presented at: the 2007 Gastrointestinal Cancers Symposium; January 19-21, 2007; Orlando, FL. Abstract 276.
8. Hochster H, Hart L, Ramanathan R, et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-study. J Clin Oncol 2006; 24(18 suppl):148s (Abstract 3510).
9. Scoggins CR, Meszoely IM, Blanke CD, et al. Nonoperative management of primary colorectal cancer in patients with stage IV disease. Ann Surg Oncol 1999; 6:651-7.
10. Tebbutt NC, Norman AR, Cunningham D, et al. Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut 2003; 52:568-73.
11. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005; 91:173-80.
12. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-16.
14. Muratore A, Zorzi D, Bouzari H, et al. Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? Ann Surg Oncol 2007; 14:766-70.
15. Sugrue M, Kozloff M, Hainsworth J, et al. Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. J Clin Oncol 2006; 24(18 suppl):154s (Abstract 3535).
16. Kretzschmar A, Cunningham D, Berry S, et al. Incidence of gastrointestinal perforations and bleeding in patients starting bevacizumab treatment in first-line mCRC without primary tumour resection: preliminary results from the first BEATrial. Presented at: the 2006 American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 26-28, 2006; San Francisco, CA. Abstract # 248.
17. Temple LK, Hsieh L, Wong WD, et al. Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol 2004; 22:3475-84.
18. Chau I, Brown G, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 2006; 24:668-74.
19. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 2006; 24:394-400.